Amgen
AMGN · What the business does, what can go wrong, and how options sellers approach it
What it does
Amgen is a biotechnology company that discovers, develops, manufactures and sells medicines for serious illnesses. Its products span inflammatory disease, bone health, cardiovascular disease, cancer, rare disease and blood-related conditions. Many of its drugs are biologics, complex medicines made in living cells rather than synthesized chemically.
Amgen also sells biosimilars, close copies of other companies' biologics after their patents expire.
How it makes money
Amgen sells prescription drugs to wholesalers, pharmacies, hospitals and health systems. Government programs and private insurers influence both the price Amgen realizes and patient access.
Biologics are hard to make, so manufacturing scale and quality control matter. Research and development is a large, ongoing cost.
Why investors own it
- Established medicines that generate steady cash flow.
- A diversified drug lineup across several disease areas.
- A history of returning cash to shareholders through dividends and buybacks (not guaranteed to continue).
- Pipeline potential, since a successful new drug can add a meaningful revenue stream.
- Defensive appeal, since medicine demand is less tied to the economic cycle.
What can go wrong
- Patent expirations and competition from biosimilars and generics can erode sales of key drugs.
- Drug pricing pressure from governments and insurers can reduce revenue.
- Clinical trials can fail, and regulators can delay or reject approvals.
- A few products drive a large share of sales, so setbacks in one can matter.
- Acquisitions can bring integration challenges and debt.
- Safety issues or manufacturing problems can lead to recalls or restrictions.
What to watch
- Sales trends for key products
- Clinical trial readouts, regulatory decisions and late-stage pipeline progress
- Patent expiration dates and biosimilar entry
- Drug pricing and reimbursement policy changes
- Dividend and buyback announcements
Options income angle
Options on AMGN are typically liquid, with active monthly expirations and reasonable strike depth near the current price.
Implied volatility tends to rise ahead of earnings, trial results, regulatory decisions and pricing news, then often eases afterward.
One caution for premium sellers: biotech stocks can gap sharply on trial or regulatory news, pushing a short option deep in the money quickly. Event dates relative to expiration matter.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 13, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Amgen reported higher sales and a large jump in profit for 2025, while the filing points to pressure on several older medicines. These include biosimilar (lower-cost copy) competition for Prolia and XGEVA, Medicare price setting for ENBREL and Otezla, and an unresolved IRS tax dispute with a decision expected no earlier than the second half of 2026.
How the business did
- Total revenues were $36,751 million, up 10%, versus $33,424 million in 2024. Product sales rose 10%, driven by volume growth of 13% and partly offset by a 3% decline in net selling price (price after rebates and discounts).
- Net income was $7,711 million versus $4,090 million, and diluted EPS was $14.23 versus $7.56. Other income included net unrealized gains on equity investments, primarily BeOne, against losses in the prior year.
- Repatha ($3,016 million, up 36%), EVENITY ($2,100 million, up 34%), BLINCYTO ($1,559 million, up 28%) and TEZSPIRE ($1,478 million, up 52%) grew on volume. ENBREL fell 33% to $2,226 million as net selling price dropped 36%, which the filing links to 340B Program mix, Medicare Part D redesign and higher commercial discounts.
- Operating expenses included R&D of $7,272 million, up 22%, led by Later-Stage Clinical Programs including MariTide, and Otezla intangible asset impairment charges of $1.2 billion.
- Operating cash flow was $10.0 billion. The company spent $1.9 billion on capital expenditures, retired $6.0 billion of debt, and raised its quarterly dividend 6% to $2.38 per share.
Risks specific to this company
- IRS tax dispute: The IRS contests how profits were allocated between the U.S. and Puerto Rico. For 2013 to 2015 it seeks additional federal tax of approximately $5.1 billion plus interest, and asserts penalties of approximately $2.0 billion. For 2010 to 2012 the figure is approximately $3.6 billion plus interest. The company says payments could be substantially greater than amounts accrued.
- Government drug pricing: CMS set Medicare prices for ENBREL effective January 1, 2026 and for Otezla effective January 2027, at significantly lower prices. The filing also describes Most-Favored-Nations pricing actions whose effect on pricing and profitability it calls uncertain.
- Biosimilar competition: Patents on the RANKL antibodies for Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select European countries. Management expects accelerated sales erosion in 2026 as multiple biosimilars have launched.
- Manufacturing concentration: A substantial majority of commercial manufacturing is in Puerto Rico, which the filing says is vulnerable to hurricanes, earthquakes and an unstable electric grid. The sole CMO producing KRYSTEXXA drug substance is in Israel, which is affected by the conflict in the Middle East.
- Customer concentration: The substantial majority of U.S. product sales goes to three wholesalers: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc. A small number of large insurers and PBMs also hold strong negotiating leverage.
- Debt: Noncurrent long-term borrowings were $50.0 billion. Credit ratings of BBB+, Baa1 and BBB+ are investment grade, and the filing says unfavorable changes may affect future financings.
What management is watching
- For 2026, management expects volume growth from certain brands to be partly offset by net selling price declines. It expects Repatha net selling price to fall by approximately mid-single digits.
- The first quarter is historically the lowest sales quarter, as U.S. patients work through deductibles and higher co-pays, notably for ENBREL and Otezla.
- Management expects to keep growing Later-Stage Clinical Programs spending. Six global Phase 3 studies for MariTide were initiated in 2025.
- Capital projects in 2026 are estimated at approximately $2.6 billion, mostly new plants and expanded manufacturing capacity.
- The company points to tariff developments and notes relief from Section 232 tariffs for approximately the next three years. It declared a first-quarter 2026 dividend of $2.52 per share and had $6.8 billion of share repurchase authorization remaining.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Amgen's total revenues rose 8% to $10,365 million for the third quarter, and diluted EPS (earnings per share) rose to $7.08 from $5.93. Growth in Repatha, UPLIZNA, EVENITY and IMDELLTRA/IMDYLLTRA outweighed steep declines in Prolia and XGEVA, which now face biosimilar (lower-priced copy) competition. Drug pricing policy and a TAVNEOS regulatory fight are the main open risks.
How the business did
- Quarter: Total product sales were $9,883 million, up 8% on volume growth. Operating income was $3,710 million versus $2,526 million a year earlier, and net income was $3,864 million versus $3,216 million. Operating expenses fell 5%, mainly from lower amortization of acquired assets and the absence of the 2025 Otezla impairment charge (a write-down of an asset's value).
- Year to date: Total revenues were $29,037 million, up 8%. Diluted EPS was $14.79 versus $11.77.
- Winners and losers: Repatha sales were $1,085 million, up 37%, and UPLIZNA reached $451 million. IMDELLTRA/IMDYLLTRA reached $406 million. Prolia fell 45% to $632 million and XGEVA fell 47% to $288 million, both on biosimilar launches. Otezla fell 18% to $481 million. ENBREL rose 5% to $611 million for the quarter, helped by favorable changes to estimated sales deductions and higher inventory despite a lower net selling price. For nine months it is down 11%, reflecting Medicare price setting.
- Cash and capital return: Operating cash flow for nine months was $10,432 million versus $8,355 million. The company paid $4.1 billion of dividends, declared a $2.52 quarterly dividend, and repurchased no shares, with $6.8 billion of authorization remaining. It issued $4.0 billion of debt and repaid $3.9 billion.
- Other income: Other income, net was $1,629 million versus $2,080 million, on lower unrealized gains on equity investments, mainly BeOne.
What management is watching
- Rest of 2026: Management expects volume growth from certain brands to be partly offset by net selling price declines, and expects continued Prolia and XGEVA erosion. Otezla faces Medicare price setting beginning in 2027.
- Spending and pipeline: R&D was $2,111 million, up 11%, on early research, business development and MariTide. Capital projects are estimated at approximately $2.6 billion for 2026. Phase 3 studies of IMDELLTRA/IMDYLLTRA (DeLLphi-305) and dazodalibep (OASIZ 301) met their primary endpoints. The FDA accepted the ABP 206 biosimilar application.
- Tax dispute: The U.S. Tax Court decision on the 2010–2015 IRS cases is expected no earlier than late 2026 or early 2027. The IRS notices seek approximately $3.6 billion and $5.1 billion of additional tax for the two periods, plus approximately $2.0 billion of penalties for 2013–2015. The company says these positions are without merit.
New or changed risks
- TAVNEOS: The FDA proposed withdrawing approval and the company requested a hearing. It submitted further data on July 23, 2026, and CDER has not yet responded. In August 2026 the European Commission revoked the EU marketing authorization held by a licensee.
- State price limits: On September 16, 2026, Washington's drug affordability board selected Otezla for review, after earlier selecting ENBREL. Colorado's upper payment limit on ENBREL is preliminarily enjoined (paused by a court).
- Medicaid pricing: The GENEROUS Model requires added Medicaid rebates, and its effect depends on how many states take part.
- 340B: The company will join a one-year 340B rebate pilot for ENBREL and Otezla starting January 2027, but says it may not fully address improper use of the program.
Follow AMGN in Kortex
The Kortex app shows AMGN's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.